Sai Parenterals to acquire majority stake in Bion Therapeutics in cash deal
Sai Parenterals · Pharmaceuticals & Biotechnology
Key highlights
- Board approved acquisition via wholly owned subsidiary SP Analytics Private Limited on 16 Nov 2026
- Bion Therapeutics (India) Pvt Ltd, incorporated in 2005, reported ₹28.22 Cr turnover for H1 FY 2026-27
- Acquisition to complete by 30 Nov 2026, funded through IPO proceeds and debt, no regulatory approval needed
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Held On Monday, 16Th November, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Engineering Services
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Sai Parenterals
- Financial resultsMajor developmentSai Parenteral's approves Sep 2026 quarter results and SP Analytics stake acquisition
- Acquisition / mergerMajor developmentSai Parenterals approves Q2 and H1 results; buyout of SP Analytics' remaining 25% approved
- Acquisition / mergerNotableSai Parenterals Limited reports Q2 & H1 FY27 results and strategic updates
Other acquisition / merger filings this fortnight
- Acquisition / mergerShalimar PaintsShalimar Paints Limited approves Scheme of Amalgamation with Hella Infra Market Limited
- Acquisition / mergerHero MotorsHero Motors Limited acquires 8039 shares of Hewland Engineering Limited
- Acquisition / mergerB-Right RealEstateB-Right Realestate Ltd enters Term Sheet for Chandani Agar SRA redevelopment
- Acquisition / mergerJindal PhotoConcatenate Power Advest Pvt Ltd acquires 1,02,583 shares of Jindal Photo Ltd via delisting
- Acquisition / mergerNisus Finance Services CoNisus Finance acquires Adaire 1 & 2 residential asset in Dubai's Jumeirah Garden City
- Acquisition / mergerCapital Infra TrustCapital Infra Trust reports Q2 FY27 results with ₹2.30 DPU and expanded AUM
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.
